Every material Form 8-K Minerva Neurosciences, Inc. has filed with the SEC since May 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Minerva Neurosciences reported GAAP net income of $100.7 million for the quarter ended September 30, 2026, compared with a net loss of $2.7 million a year earlier. The company said the result was driven by a $109.6 million non-cash gain from changes in the fair value of its warrant liability, and excluding that gain and stock-based compensation, its adjusted net loss widened to $5.6 million from $2.5 million. For shareholders, the operating loss grew as research and development and general and administrative spending rose, and cash and equivalents fell to about $77.0 million.
GAAP net income of $100.7 million, or $1.94 per basic share and $(0.19) per diluted share, for the three months ended September 30, 2026, versus a net loss of $2.7 million a year earlier.
Non-cash warrant liability gain of $109.6 million; adjusted net loss was $5.6 million versus $2.5 million in the prior-year quarter.
R&D expense was $5.2 million versus $0.9 million, and G&A expense was $4.3 million versus $1.9 million.
Cash, cash equivalents, marketable securities and restricted cash were about $77.0 million at September 30, 2026, down from $82.4 million at December 31, 2025.
Minerva Neurosciences' board appointed Anthony Aliquo, its Vice President and Controller, as chief accounting officer and principal accounting officer effective August 10, 2026. CFO Fred Ahlholm stepped back from the principal accounting officer role but remains chief financial officer and principal financial officer. The change is an internal reassignment of accounting oversight, with a salary increase and higher bonus target for Aliquo.
Anthony Aliquo, age 39, appointed chief accounting officer effective August 10, 2026
Fred Ahlholm continues as Chief Financial Officer and principal financial officer
Aliquo's base salary increased to $296,696, effective July 1, 2026
Aliquo's annual performance bonus target raised to 35% of base salary
Minerva Neurosciences reported second quarter 2026 results, showing GAAP net income of $17.5 million, driven by a $27.6 million non-cash gain on its warrant liability. Adjusted net loss widened to $7.8 million from $3.0 million a year earlier, and cash, equivalents and marketable securities fell to $75.4 million from $82.4 million at December 31, 2025, so shareholders face higher operating costs ahead of the confirmatory Phase 3 trial's topline data in the second half of 2027.
Q2 2026 GAAP net income was $17.5 million, or $0.36 per basic share, versus a net loss of $3.3 million a year earlier.
Six-month GAAP net loss was $107.9 million, or $2.38 per share, including an $81.8 million non-cash warrant liability loss.
R&D expense rose to $7.2 million in Q2 from $1.3 million, mainly due to the C19 trial; G&A rose to $3.5 million from $2.1 million.
Confirmatory Phase 3 C19 trial is designed to enroll 380 patients, with Phase A topline data expected in 2H 2027.
Minerva Neurosciences entered a Sales Agreement with Leerink Partners LLC for an at-the-market offering of up to $75.0 million of common stock, with a 3.0% commission on gross proceeds. The company is not obligated to sell any shares, so the program could dilute existing shareholders if used. The filing also says the relapse assessment phase of its Phase 3 C19 trial of roluperidone was extended from 40 weeks to 52 weeks after FDA feedback, with topline results still expected in the second half of 2027.
Up to $75.0 million of common stock may be sold through Leerink Partners LLC, under a prospectus supplement dated May 27, 2026
Agent commission is 3.0% of gross proceeds; the company has no obligation to sell any shares
Relapse assessment phase of the C19 trial extended from 40 weeks to 52 weeks after FDA feedback
Topline efficacy results still expected in the second half of 2027; relapse assessment data in the second half of 2028
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Minerva Neurosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →